NCT07198373View on ClinicalTrials.gov

Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma

Not yet recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

September 20, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions
B Cell Lymphoma
Interventions
DRUG

Maintenance Therapy Group

Patients achieving remission (complete or partial) at the 3-month post-CAR-T infusion assessment receive oral zanubrutinib capsules for maintenance therapy for 2 years.

All Listed Sponsors
lead

Beijing GoBroad Hospital

OTHER